Symptom Tracking using TempusPRO in Patients with Pharmacogenetic Testing From a Real-World Dataset

Abstract: Background Patients with neuropsychiatric illness have inconsistent responses to medications. Pharmacogenomic testing (PGx) helps identify patients who may better respond to certain medications or carry a greater risk of adverse events. Mobile health apps, like TempusPRO, administer measurement-based care (MBC) to track symptom severity longitudinally and in real-time. Here, we combine PGx and MBC tools into a single platform to further improve patient care. Methods We normalized symptom severity scores recorded through TempusPRO to be between 0-1 and compared severity before and after PGx across all assessments (Nf355 patients) and on individual assessments completed by ≥20 patients with >2 questions (Nf302 patients). User experience was also measured by analyzing patient engagement and retention with TempusPRO (Nf635 patients). Results Symptom severity decreased following PGx combined with TempusPRO monitoring (-8%, matched-pair t-test P=4e-16). Symptom severities decreased on all 6 individual questionnaires tested. Overall, average user engagement was 5.3 assessments over a 47-day retention period. Patients who received PGx were found to have higher engagement and retention versus patients without PGx (6 vs 4 assessments, 55 vs 26 days, wilcoxon ranked sum test P=7.8e-08 P=3.8e-06). Higher symptom severity was associated with shorter retention, while frequent engagement was associated with improved symptoms. Conclusion This analysis utilized digital, out-of-office MBC to quantify symptom trajectories from real-world data following PGx. Our preliminary findings suggest further investigation is warranted for the use of PGx and mobile-app based MBC together, to better inform treatment decisions in clinical settings.Short Description: Pharmacogenomic testing (PGx) can guide treatment approaches in patients with psychiatric illnesses. Here, we combined PGx and measurement-based care (MBC) tools into a single platform, comparing symptom severity before and after PGx, monitored through the TempusPRO MBC mobile application. Symptom severity decreased following PGx (Nf355, -8%) and PGx was associated with improved user experience. Thus, further investigation is warranted for the combined use of PGx and mobile application-based MBC to better inform treatment decisions.Name of Sponsoring Organization(s): Tempus Labs